Literature DB >> 15737765

Use of recombinant factor VII to control bleeding in a patient supported by right ventricular assist device after heart transplantation.

Alexander Kogan1, Marius Berman, Ygal Kassif, Ehud Raanani, Alon Stamler, Tuvia Ben Gal, Michael Stein, Eldad Erez, Bernardo A Vidne, Gideon Sahar.   

Abstract

A 48-year-old man undergoing orthotopic heart transplantation for ischemic cardiomyopathy developed severe right heart failure. Severe intractable bleeding complicated implantation of a right ventricular assist device. Treatment with 9.6 mg of recombinant activated factor VII stopped the bleeding, and the patient could be transferred to the intensive care unit. This is the first reported case of the successful use of recombinant activated factor VII to control bleeding with subsequent right ventricular assist device function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737765     DOI: 10.1016/j.healun.2003.12.001

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  2 in total

1.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637

Review 2.  Recombinant activated factor VII (Novo7) in patients with ventricular assist devices: case report and review of the current literature.

Authors:  Daniel Heise; Anselm Bräuer; Michael Quintel
Journal:  J Cardiothorac Surg       Date:  2007-10-26       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.